ALVAC-RG Rabies Glycoprotein (vCP65)
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
HIV InfectionsHIV Seronegativity
Phase 1
A Study to Test the Safety of Three Experimental HIV Vaccines
CompletedNCT00000946
End: 2001-03-31Target: 40Updated: 2021-10-29
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
CompletedNCT00000847
End: 1999-05-31Target: 150Updated: 2021-11-04
Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults
CompletedNCT00000904
End: 1999-08-31Target: 100Updated: 2021-11-04
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
CompletedNCT00001072
End: 1999-01-31Target: 140Updated: 2021-11-04
Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda
CompletedNCT00007423
End: 2001-09-30Target: 40Updated: 2021-11-01
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules
CompletedNCT00001076
End: 1997-12-31Target: 34Updated: 2021-11-04
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers
CompletedNCT00000813
End: 1995-06-30Target: 28Updated: 2021-11-04
A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers
CompletedNCT00000884
End: 2000-10-31Updated: 2021-10-29
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers
CompletedNCT00001055
End: 1997-11-30Target: 76Updated: 2021-11-04